This HTML5 document contains 107 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00211/identifier/chebi/
n16http://linked.opendata.cz/resource/AHFS/
n22http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00211/identifier/wikipedia/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00211/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00211/identifier/kegg-compound/
n23http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB00211/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n5http://linked.opendata.cz/resource/drugbank/drug/DB00211/identifier/pubchem-substance/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00211/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n29http://www.drugs.com/cdi/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00211/identifier/national-drug-code-directory/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/sukl/drug/
n17http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00211/identifier/chemspider/

Statements

Subject Item
n2:DB00211
rdf:type
n3:Drug
n3:description
An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. [PubChem]
n3:dosage
n19:271B5CC1-363D-11E5-9242-09173F13E4C5 n19:271B5CC2-363D-11E5-9242-09173F13E4C5 n19:271B5CC3-363D-11E5-9242-09173F13E4C5 n19:271B5CC0-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Hebenstreit G: [Treatment of hypotension caused by psychopharmacological drugs (author's transl)] Wien Med Wochenschr. 1981 Feb 28;131(4):109-12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6165144 # Tsuda M, Terada T, Irie M, Katsura T, Niida A, Tomita K, Fujii N, Inui K: Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. Epub 2006 Apr 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16597710
n3:group
approved
n3:halfLife
The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours.
n3:indication
For the treatment of symptomatic orthostatic hypotension (OH).
n3:manufacturer
n22:271B5CB6-363D-11E5-9242-09173F13E4C5 n22:271B5CB7-363D-11E5-9242-09173F13E4C5 n22:271B5CB4-363D-11E5-9242-09173F13E4C5 n22:271B5CB5-363D-11E5-9242-09173F13E4C5 n22:271B5CB2-363D-11E5-9242-09173F13E4C5 n22:271B5CB3-363D-11E5-9242-09173F13E4C5
owl:sameAs
n21:DB00211 n23:DB00211
dcterms:title
Midodrine
adms:identifier
n5:46507373 n6:4195 n7:C07890 n9:0245-0211-11 n10:DB00211 n11:6933 n12:4050 n27:PA164749381 n28:Midodrine
n3:mechanismOfAction
Midodrine forms an active metabolite, desglymidodrine, that is an alpha<sub>1</sub>-agonist, and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac beta-adrenergic receptors.
n3:packager
n22:271B5CA6-363D-11E5-9242-09173F13E4C5 n22:271B5CA9-363D-11E5-9242-09173F13E4C5 n22:271B5CAA-363D-11E5-9242-09173F13E4C5 n22:271B5CA7-363D-11E5-9242-09173F13E4C5 n22:271B5CA8-363D-11E5-9242-09173F13E4C5 n22:271B5CAD-363D-11E5-9242-09173F13E4C5 n22:271B5CAE-363D-11E5-9242-09173F13E4C5 n22:271B5CAB-363D-11E5-9242-09173F13E4C5 n22:271B5CAC-363D-11E5-9242-09173F13E4C5 n22:271B5CAF-363D-11E5-9242-09173F13E4C5 n22:271B5CA2-363D-11E5-9242-09173F13E4C5 n22:271B5CA3-363D-11E5-9242-09173F13E4C5 n22:271B5CA0-363D-11E5-9242-09173F13E4C5 n22:271B5CA1-363D-11E5-9242-09173F13E4C5 n22:271B5CB0-363D-11E5-9242-09173F13E4C5 n22:271B5CB1-363D-11E5-9242-09173F13E4C5 n22:271B5CA4-363D-11E5-9242-09173F13E4C5 n22:271B5CA5-363D-11E5-9242-09173F13E4C5
n3:synonym
DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid (+-)-2-amino-N-(beta-Hydroxy-2,5-dimethoxyphenethyl)acetamide Midodrin 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide Midodrina Midodrinum 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol
n3:toxicity
Symptoms of overdose could include hypertension, piloerection (goosebumps), a sensation of coldness and urinary retention. The single doses that would be associated with symptoms of overdosage or would be potentially life- threatening are unknown. The oral LD<sub>50</sub> is approximately 30 to 50 mg/kg in rats, 675 mg/kg in mice, and 125 to 160 mg/kg in dogs. Desglymidodrine is dialyzable.
n15:hasAHFSCode
n16:12-12-00 n16:12-12-04
n3:foodInteraction
Take without regard to meals.
n3:salt
n3:synthesisReference
Anup K. Ray, Hiren Patel, Mahendra R. Patel, "Synthesis of midodrine HCI from a novel intermediate 1-(2',5'-dimethoxyphenyl)-2-azidoethanone." U.S. Patent US6201153, issued July, 1965.
n24:hasConcept
n25:M0013860
foaf:page
n14:midodrine.htm n29:midodrine.html
n3:IUPAC-Name
n8:271B5CC8-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B5CCE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B5CCD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B5CCA-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B5CCB-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B5CCC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B5CDE-363D-11E5-9242-09173F13E4C5 n8:271B5CC6-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B5CE0-363D-11E5-9242-09173F13E4C5 n8:271B5CC7-363D-11E5-9242-09173F13E4C5 n8:271B5CC4-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B5CC5-363D-11E5-9242-09173F13E4C5
n3:pKa
n8:271B5CE1-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n17:C01CA17
n3:H-Bond-Acceptor-Count
n8:271B5CD4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B5CD5-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B5CCF-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B5CD0-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B5CD2-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B5CD1-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B5CD3-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following oral administration. The absolute bioavailability of midodrine (measured as desglymidodrine) is 93% and is not affected by food.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
133163-28-7
n3:category
n3:clearance
* Renal cl=385 mL/minute
n3:containedIn
n18:271B5CB9-363D-11E5-9242-09173F13E4C5 n18:271B5CBA-363D-11E5-9242-09173F13E4C5 n18:271B5CB8-363D-11E5-9242-09173F13E4C5 n18:271B5CBD-363D-11E5-9242-09173F13E4C5 n18:271B5CBE-363D-11E5-9242-09173F13E4C5 n18:271B5CBB-363D-11E5-9242-09173F13E4C5 n18:271B5CBC-363D-11E5-9242-09173F13E4C5 n18:271B5CBF-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B5CDA-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B5CDC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B5CDD-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B5CDF-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B5CD9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B5CD8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B5CDB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B5CC9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B5CD6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B5CD7-363D-11E5-9242-09173F13E4C5